ARTICLE | Clinical News
RSD1235 IV regulatory update
April 3, 2006 7:00 AM UTC
The partners submitted an NDA to FDA for the IV formulation of RSD1235 to treat acute atrial fibrillation (AF). Astellas has North America rights to the IV mixed ion channel antagonist. ...